| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Göteborg, Sweden
2 From the Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden
Sven-Erik Ricksten, MD, PhD, Department for Anesthesia and Intensive Care, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
Study objective: Elevated pulmonary vascular resistance is a risk factor in heart transplantation and reversibility of high pulmonary vascular resistance is evaluated preoperatively in potential recipients using IV vasodilators or inhaled nitric oxide. Prostacyclin is a potent vasodilator, which when inhaled, has selective pulmonary vasodilatory properties. The aim of this study was to compare the central hemodynamic effects of inhaled prostacyclin with those of inhaled nitric oxide in heart transplant candidates.
Design: A pharmacodynamic comparative study.
Setting: Cardiothoracic ICU or laboratory for diagnostic heart catheterization at a university hospital.
Patients: Ten heart transplant candidates with elevated pulmonary vascular resistance (>200 dynes·s·cm5 and/or a transpulmonary pressure gradient > 10 mm Hg) were included in the study.
Interventions: Nitric oxide (40 ppm) and aerosolized prostacyclin (10 µg/mL) were administered by inhalation in two subsequent 10-min periods. Hemodynamic measurements preceeded and followed inhalation of each agent.
Measurements and results: Both inhaled nitric oxide and inhaled prostacyclin reduced mean pulmonary artery pressure (
7% vs7%), pulmonary vascular resistance (43% vs 49%), and the transpulmonary gradient (44% vs 38%). With inhaled prostacyclin, an 11% increase in cardiac output was observed. Other hemodynamic variables, including the systemic BP, remained unaffected by each of the agents.
Conclusions: Inhaled prostacyclin induces a selective pulmonary vasodilation that is comparable to the effect of inhaled nitric oxide. Major advantages with inhaled prostacyclin are its lack of toxic reactions and easy administration as compared with the potentially toxic nitric oxide requiring more complicated delivery systems.
Key Words: aerosolized prostacyclin • heart transplantation • inhalation • nitric oxide • pulmonary hypertension
Submitted on November 19, 1997
Accepted on March 2, 1998
This article has been cited by other articles:
|
|
 |
|
  A. Y. Denault, Y. Lamarche, P. Couture, F. Haddad, J. Lambert, J.-C. Tardif, and L. P. Perrault Inhaled milrinone: a new alternative in cardiac surgery? Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 346 - 360. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Sablotzki, W. Starzmann, R. Scheubel, S. Grond, and E. G. Czeslick Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates: [La vasodilatation pulmonaire selective avec l'inhalation de milrinone en aerosol chez des candidats a la greffe cardiaque] Can J Anesth, December 1, 2005; 52(10): 1076 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. De Wet, D. G. Affleck, E. Jacobsohn, M. S. Avidan, H. Tymkew, L. L. Hill, P. B. Zanaboni, N. Moazami, and J. R. Smith Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1058 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Reily, E. Tollok, K. Mallitz, C. W. Hanson III, and B. D. Fuchs Successful Aeromedical Transport Using Inhaled Prostacyclin for a Patient With Life-Threatening Hypoxemia Chest, April 1, 2004; 125(4): 1579 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wang, D. El Kebir, and G. Blaise Inhaled nitric oxide in 2003: a review of its mechanisms of action: [L'inhalation de monoxyde d'azote en 2003 : une revue de ses mecanismes et de son action] Can J Anesth, October 1, 2003; 50(8): 839 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sablotzki, E. Czeslick, E. Gruenig, I. Friedrich, S. Schubert, J. Borgermann, and T. Hentschel First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance J. Thorac. Cardiovasc. Surg., April 1, 2003; 125(4): 960 - 962. [Full Text] [PDF]
|
|
|
|
|
|
M. Hache, A. Denault, S. Belisle, D. Robitaille, P. Couture, P. Sheridan, M. Pellerin, D. Babin, N. Noel, M.-C. Guertin, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 642 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sablotzki, E. Czeslick, S. Schubert, I. Friedrich, J. Muhling, M. G. Dehne, S. Grond, and T. Hentschel Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension: [L'iloprost ameliore l'hemodynamique chez des malades souffrant d'insuffisance cardiaque chronique et d'hypertension arterielle pulmonaire] Can J Anesth, December 1, 2002; 49(10): 1076 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sablotzki, T. Hentschel, E. Gruenig, S. Schubert, I. Friedrich, J. Muhling, M. G. Dehne, and E. Czeslick Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 746 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Theodoraki, P. Rellia, A. Thanopoulos, L. Tsourelis, D. Zarkalis, P. Sfyrakis, and T. Antoniou Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass: [L'inhalation d'iloprost permet de controler l'hypertension pulmonaire apres la circulation extracorporelle] Can J Anesth, November 1, 2002; 49(9): 963 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Haraldsson, N. Kieler-Jensen, and S.-E. Ricksten The Additive Pulmonary Vasodilatory Effects of Inhaled Prostacyclin and Inhaled Milrinone in Postcardiac Surgical Patients with Pulmonary Hypertension Anesth. Analg., December 1, 2001; 93(6): 1439 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs] Can J Anesth, October 1, 2001; 48(9): 924 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Monnery, J. Nanson, and G. Charlton Primary pulmonary hypertension in pregnancy; a role for novel vasodilators Br. J. Anaesth., August 1, 2001; 87(2): 295 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schenk, V. Petkov, C. Madl, L. Kramer, M. Kneussl, R. Ziesche, and I. Lang Aerosolized Iloprost Therapy Could Not Replace Long-term IV Epoprostenol (Prostacyclin) Administration in Severe Pulmonary Hypertension Chest, January 1, 2001; 119(1): 296 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Schroeder, G. L. Wood, J. S. Plotkin, and P. C. Kuo Intraoperative Use of Inhaled PGI2 for Acute Pulmonary Hypertension and Right Ventricular Failure Anesth. Analg., August 1, 2000; 91(2): 291 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. van Heerden, A. Barden, N. Michalopoulos, M. K. Bulsara, and B. L. Roberts Dose-Response to Inhaled Aerosolized Prostacyclin for Hypoxemia Due to ARDS Chest, March 1, 2000; 117(3): 819 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ashutosh, K. Phadke, J. F. Jackson, and D. Steele Use of nitric oxide inhalation in chronic obstructive pulmonary disease Thorax, February 1, 2000; 55(2): 109 - 113. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
